Zhejiang Shouxiangu Pharmaceutical Co., Ltd.
SSE:603896.SS
22.31 (CNY) • At close June 6, 2025
Overview | Financials
Cijfers zijn in miljoenen (behalve de cijfers per aandeel en de ratio's) CNY.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operationele Activiteiten: | |||||||||||||
| Nettowinst
| 174.715 | 254.48 | 277.513 | 200.311 | 151.712 | 123.895 | 107.653 | 88.88 | 80.978 | 62.644 | 69.251 | 54.048 | 34.023 |
| Afschrijvingen & Amortisatie
| 78.982 | 76.223 | 64.377 | 53.897 | 43.335 | 41.039 | 38.805 | 36.622 | 39.071 | 35.423 | 20.844 | 1.42 | 1.263 |
| Uitgestelde Inkomstenbelasting
| 0 | 0 | -0.211 | 0.667 | -0.017 | -0.721 | 0.312 | -0.053 | 0 | 0 | 0 | 0 | 0 |
| Aandelen Gebaseerde Vergoedingen
| 0 | 0 | 0 | 4.391 | 18.741 | 42.736 | 35.297 | 0 | 0 | 0 | 0 | 0 | 0 |
| Verandering in Werkkapitaal
| -70.164 | -51.734 | -26.409 | 9.483 | 22.747 | 2.715 | -9.272 | -17.542 | -37.404 | -25.045 | 10.578 | 0 | 0 |
| Vorderingen
| -34.929 | -18.97 | -16.192 | -27.896 | -18.377 | -9.065 | -23.858 | -9.579 | -1.297 | -3.07 | 8.482 | 0 | 0 |
| Voorraden
| -21.718 | -10.077 | -48.695 | 0.316 | 10.717 | 8.522 | -5.916 | -11.58 | -22.549 | -20.091 | -1.661 | 0 | 0 |
| Crediteuren
| 0 | -22.688 | 38.689 | 36.396 | 30.424 | 3.978 | 20.19 | 3.669 | 0 | 0 | 0 | 0 | 0 |
| Overig Werkkapitaal
| -13.518 | -0 | -0.211 | 0.667 | -0.017 | -0.721 | -3.356 | -5.962 | -14.855 | -4.954 | 12.24 | 0 | 0 |
| Overige Niet-Contante Posten
| 29.907 | 36.089 | 25.802 | 27.95 | 19.84 | -1.747 | 34.327 | 2.844 | 12.871 | 12.008 | 2.226 | -54.048 | -34.023 |
| Kasstroom uit Operationele Activiteiten
| 213.44 | 315.057 | 341.283 | 296.699 | 256.359 | 207.918 | 171.513 | 110.804 | 95.517 | 85.029 | 102.899 | 65.85 | 45.357 |
| Investeringsactiviteiten: | |||||||||||||
| Investeringen in Materiële Vaste Activa
| -507.059 | -414.54 | -182.601 | -161.625 | -64.979 | -91.486 | -232.843 | -31.448 | -40.25 | -130.873 | -136.166 | -113.471 | -48.302 |
| Netto Overnames
| 0 | 0.109 | -0.817 | 0.953 | 64.979 | 91.52 | 0 | 31.448 | -11.733 | 0 | 1.479 | 0 | 0.216 |
| Aankoop van Beleggingen
| -1,174.75 | -1,450 | -158.225 | -458.2 | -465.52 | -711.5 | -603.78 | -675.041 | -578.618 | -160.75 | -90.468 | -42.577 | -41 |
| Verkoop/verval van Beleggingen
| 1,211.868 | 565.649 | 256.248 | 386.051 | 620.149 | 749.054 | 587.591 | 461.327 | 585.626 | 143.456 | 83.776 | 40.177 | 46.24 |
| Overige Investeringsactiviteiten
| 230.184 | 0 | 0 | -0.9 | -64.979 | -91.486 | 0 | -31.448 | 0 | 2.873 | 0.45 | 1 | 10.506 |
| Kasstroom uit Investeringsactiviteiten
| -239.758 | -1,298.783 | -85.394 | -233.721 | 89.65 | -53.898 | -249.032 | -245.162 | -44.974 | -145.294 | -140.929 | -114.871 | -32.34 |
| Financieringsactiviteiten: | |||||||||||||
| Schuldaflossingen
| -145.996 | 135.783 | 661.942 | -0.019 | 341.493 | -30 | 0 | -123 | -44.6 | 0 | 49.5 | 4.5 | 7 |
| Uitgifte van Gewone Aandelen
| 0 | 0 | 0 | 2.098 | 173.132 | 2.955 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Terugkoop van Gewone Aandelen
| 0 | 0 | 0 | -2.098 | -173.132 | -2.955 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Uitgekeerde Dividenden
| -83.002 | -92.78 | -60.317 | -45.886 | -49.371 | -33.066 | -28.973 | -18.845 | -19.505 | -25.997 | -47.875 | -33.412 | -33.645 |
| Overige Financieringsactiviteiten
| -14.386 | 247.078 | -265.786 | -9.237 | -1.374 | 9.6 | 125.019 | 360.719 | 0 | 63.6 | 0.486 | 106.907 | 28.602 |
| Kasstroom uit Financieringsactiviteiten
| -243.384 | 290.081 | 335.839 | -54.242 | 117.616 | -56.421 | 96.352 | 218.874 | -64.105 | 37.603 | 1.8 | 77.995 | 1.957 |
| Overige Informatie: | |||||||||||||
| Effect van Wisselkoersveranderingen op Kas
| 0 | 0 | 0 | 0 | 0 | -0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Netto Kasstroomverandering
| -269.702 | -693.644 | 591.729 | 8.735 | 463.625 | 97.599 | 18.833 | 84.516 | -13.562 | -22.661 | -36.23 | 28.974 | 14.974 |
| Kaspositie aan het Einde van de Periode
| 306.367 | 576.068 | 1,269.712 | 677.984 | 669.248 | 205.624 | 108.024 | 89.191 | 4.675 | 18.238 | 40.899 | 77.13 | 48.155 |